SCHEMBL20164076

SCHEMBL20164076

CCCCNC(=O)c1ccnc(-c2cc(C(=O)NCCCC)ccn2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.69
KDM5A P29375 2/20 0.64
KDM4E B2RXH2 4/20 0.61
NAAA Q02083 2/20 0.59
KDM5B Q9UGL1 2/20 0.57
KDM5C P41229 1/20 0.57
SMYD2 Q9NRG4 1/20 0.54
RXFP1 Q9HBX9 1/20 0.50
TSHR P16473 1/20 0.50
HTT P42858 1/20 0.50
L3MBTL1 Q9Y468 3/20 0.49
HPGD P15428 3/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.49
POLB P06746 1/20 0.49
ALOX15 P16050 1/20 0.49
CASP1 P29466 1/20 0.49
BLM P54132 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7956332 0.94 NAAA (0.68) SMN1; SMN2KDM5AKDM4ENAAAKDM5B
SCHEMBL7966788 0.94 NAAA (0.68) SMN1; SMN2KDM5AKDM4ENAAAKDM5B
SCHEMBL9792819 0.90 KDM4E (0.64) SMN1; SMN2KDM5AKDM4ENAAAKDM5B
SCHEMBL11627803 0.85 SMN1; SMN2 (0.60) SMN1; SMN2KDM5AKDM4ENAAARXFP1
SCHEMBL7963734 0.83 KDM4E (0.59) SMN1; SMN2KDM5AKDM4EKDM5BKDM5C
SCHEMBL16117373 0.82 SMN1; SMN2 (1.00) SMN1; SMN2NAAATSHRHTTL3MBTL1
SCHEMBL12308117 0.81 KDM4E (0.64) SMN1; SMN2KDM5AKDM4EKDM5BKDM5C
SCHEMBL10242958 0.80 SMN1; SMN2 (0.67) SMN1; SMN2NAAARXFP1TSHRHTT
SCHEMBL3634350 0.80 NAAA (0.87) SMN1; SMN2KDM4ENAAATSHRHTT
SCHEMBL13383595 0.80 KDM4E (0.84) KDM5AKDM4EKDM5BKDM5CSMYD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759994-B2 Luminogenic transition metal-based pyridyl complex and its use CITY UNIVERSITY OF HONG KONG (HK) 2020-09-01 US disclosed
US-10759994-B2 Luminogenic transition metal-based pyridyl complex and its use CITY UNIVERSITY OF HONG KONG (HK) 2020-09-01 US disclosed
US-20180142144-A1 LUMINOGENIC TRANSITION METAL-BASED PYRIDYL COMPLEX AND ITS USE CITY UNIVERSITY OF HONG KONG (HK) 2018-05-24 US disclosed
US-20180142144-A1 LUMINOGENIC TRANSITION METAL-BASED PYRIDYL COMPLEX AND ITS USE CITY UNIVERSITY OF HONG KONG (HK) 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10759994-B2 Luminogenic transition metal-based pyridyl complex and its use TK1, NOX5, PDXK SMN1; SMN2 3154/4885KDM5A 2086/4885KDM4E 3901/4885
US-20180142144-A1 LUMINOGENIC TRANSITION METAL-BASED PYRIDYL COMPLEX AND ITS USE TK1, NOX5, PDXK SMN1; SMN2 3154/4885KDM5A 2086/4885KDM4E 3901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.